Author:
Samala Niharika,Chalasani Naga
Publisher
Springer Science and Business Media LLC
Reference96 articles.
1. On behalf of the Practice Parameters Committee of the American College of Gastroenterology, Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109:950–66.
2. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 2010;51:615–20.
3. Wang B, Avorn J, Kesselheim AS. Clinical and regulatory features of drugs not initially approved by the FDA. Clin Pharmacol Ther. 2013;94:670–7.
4. •• Clinical course and diagnosis of drug induced liver disease [Internet]. National Library Of Medicine and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Available from: https://livertox.nih.gov/ClinicalCourse.html . LiverTox is an authoritative online resource for drug-induced liver injury developed by Liver Diseases Branch, NIDDK in collaboration with Division of Specialized Information Services, National Library of Medicine.
5. •• Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95. Landmark population-based study in the USA reporting prevalence of nonalcoholic fatty liver disease based in a multi-ethnic population based on magnetic resonance spectroscopy imaging.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献